Nisha Holay

Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy

Milad Soleimani, Alexander Somma, Tamer S. Kaoud et al. · Molecular Cancer Therapeutics · 2022 · 18 citations

Life Sciences, Cancer Biology, Oncology +17

The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming

Annah S. Rolig, Xiyu Peng, Elizabeth R. Sturgill et al. · Science Translational Medicine · 2025 · 14 citations · Full text

Life Sciences, Immunology, Oncology +17

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Nisha Holay, Rashi Yadav, Sae Jeong Ahn et al. · Journal for ImmunoTherapy of Cancer · 2025 · 14 citations · Full text

Life Sciences, Immunology, Oncology +17

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

Anna Schreiber, Jodi Kagihara, Bradley R. Corr et al. · Cancers · 2023 · 11 citations · Full text

Medicine, Oncology, Pharmacology +15

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy

Nisha Holay, Alexander Somma, Mark Duchow et al. · Frontiers in Immunology · 2023 · 10 citations · Full text

Life Sciences, Immunology, Pharmacology +17